Logo

Invitrogen Offers $300M in Convertible Notes to Repay Credit Line, Possibly Fund More M&A

Jun 14, 2005

NEW YORK, June 14 (GenomeWeb News) - Invitrogen said yesterday that it intends to offer $300 million of senior convertible notes due 2025.

 

Invitrogen said that purchasers of the notes will have an option to purchase up to an additional $50 million to cover over-allotments.

 

The company said it will use some of the net proceeds of the offering to repay around $124 million borrowed a revolving line of credit with Bank of America.

 

Invitrogen said it intends to use the balance of the net proceeds for "potential acquisitions and for general corporate purposes, including the potential repayment or redemption of other outstanding debt."

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.